[1] |
Moll UM, Petrenko O. The MDM2-p53 Interaction[J]. Mol Cancer Res,2003, 1:1001. |
[2] |
Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain[J]. Science, 1996, 274:948. |
[3] |
Garcia-Echeverria C, Chene P, Blommers MJJ. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53[J].J Med Chem, 2000, 43:3205. |
[4] |
Baek S, Kutchukian PS, Verdine GL, et al. Structure of the stapled p53 peptide bound to Mdm2[J].J Am Chem Soc, 2012, 134:103. |
[5] |
Lyubomir T, Vassilev BT, Bradford G, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2[J]. Science, 2004, 303:844. |
[6] |
Yu S, Qin D, Shangary S, et al. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction[J]. J Med Chem, 2009, 52:7970. |
[7] |
Marugan JJ, Leonard K, Raboisson P, et al. Enantiomerically pure 1,4-benzo-diazepine-2,5-diones as MDM2 antagonists[J]. Bioorg Med Chem Lett, 2006,16:3115. |